Goldman Sachs Suggests Buying Calls on United Therapeutics (UTHR)

Goldman Sachs is out with a research note this morning, where it suggests that traders buy calls on United Therapeutics Corporation UTHR ahead of FREEDOM data. On March 9, Goldman recommended that investors buy the August $75 call for $8.39 (stock $68.69), and sell the Jan-12 $90 call for $5.80 to help fund the purchase ahead of several key catalysts, including earnings and June data on FREEDOM, the biotech's main drug to treat Pulmonary Arterial Hypertension (PAH). As we get closer to the critical June date, Goldman now recommends that investors close the Jan-12 call sale at a gain (ask $4.60) and add to August $75 calls, to increase upside potential into the event. United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic diseases.